Semaglutide 14 mg (Rybelsus)

Price range: $214.00 through $589.00

Semaglutide 14 mg Tablets are an oral semaglutide presentation in the GLP-1 receptor agonist class. In the FDA-approved Rybelsus 3 mg / 7 mg / 14 mg regimen, 14 mg is the higher maintenance strength that may be used when additional glycemic control is needed after treatment at 7 mg. Use only under prescription guidance and verify the exact product identity before making brand or generic-equivalence claims.Product at a Glance

Product Detail Information
Active ingredient Semaglutide
Listed strength 14 mg
Dosage form Oral tablet
Presentation Tablet
Pack / quantity options Use the current WooCommerce tablet quantity variations already configured on the live product
Drug class GLP-1 receptor agonist
Prescription / clinical guidance Use only in accordance with applicable prescribing and dispensing requirements
Compare
Add to wishlist
SKU: N/A Categories: ,

Description

Semaglutide is a GLP-1 receptor agonist available in multiple prescription formulations. FDA-approved Rybelsus includes a 14 mg tablet within its established 3 mg / 7 mg / 14 mg oral regimen.

What are Semaglutide 14 mg Tablets?
Semaglutide 14 mg is an oral GLP-1 receptor agonist strength. In the FDA-approved Rybelsus 3 mg / 7 mg / 14 mg regimen, 14 mg can be used from Day 61 or later when additional glycemic control is needed after 7 mg, as determined by the prescribing healthcare professional.

How Semaglutide Works
Semaglutide activates GLP-1 receptors. Its pharmacologic effects include glucose-dependent stimulation of insulin secretion, reduction of glucagon when glucose is elevated, delayed gastric emptying and effects on appetite and satiety.

Role of the 14 mg Strength
In the current FDA-approved Rybelsus 3/7/14 mg regimen, treatment begins with 3 mg once daily for 30 days and then 7 mg once daily. From Day 61 or later, 14 mg may be used if additional glycemic control is needed. Dose escalation is a clinical decision and should not be based solely on appetite, body weight or information on a retail website.

Administration of FDA-Approved Rybelsus
The FDA label directs patients to take Rybelsus once daily in the morning on an empty stomach with up to 4 ounces of water. The tablet is swallowed whole, and patients wait at least 30 minutes before eating, drinking other beverages or taking other oral medicines.

Product Identity Matters
Do not assume that all products labeled “oral semaglutide 14 mg” are the FDA-approved Rybelsus formulation. Before publishing brand references, identify the manufacturer, formulation and regulatory status of the supplied product.

Important Safety Information
Semaglutide is a GLP-1 receptor agonist and is not appropriate for every patient. Approved semaglutide products carry important warnings and contraindications. A healthcare professional should review the patient’s medical history, current medicines and treatment goals before use.

Common adverse reactions reported with approved semaglutide products are mainly gastrointestinal and can include nausea, vomiting, diarrhea, abdominal pain and constipation. Serious reactions can also occur, including pancreatitis, gallbladder problems, kidney injury related to volume depletion, severe gastrointestinal reactions, hypersensitivity reactions and complications of diabetic retinopathy in some patients.

Approved semaglutide labeling includes a boxed warning concerning the risk of thyroid C-cell tumors observed in rodents. Semaglutide products are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The relevance of the rodent findings to humans has not been established.

Tell your healthcare professional about planned surgery or procedures requiring general anesthesia or deep sedation, and discuss pregnancy or plans for pregnancy. This summary is not a substitute for the complete prescribing information for the exact product supplied.

Who Should Speak With a Healthcare Professional Before Use?

  • Anyone considering semaglutide should have the exact product, indication and dose assessed by a qualified healthcare professional.
  • Discuss a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2, previous pancreatitis, gallbladder disease, kidney problems, severe gastrointestinal disease, diabetic retinopathy and serious allergies.
  • Tell the prescriber about insulin, sulfonylureas and other medicines that can affect blood glucose, as well as other oral medicines when using oral semaglutide.
  • Discuss pregnancy, plans for pregnancy or breastfeeding before treatment. Current FDA labeling advises discontinuation of semaglutide at least 2 months before a planned pregnancy because of its long washout period.
  • Tell healthcare providers about semaglutide before planned surgery or deep sedation because GLP-1 receptor agonists delay gastric emptying and pulmonary aspiration has been reported.

The information on this page is provided for general educational and product-information purposes and is not medical advice, diagnosis or a substitute for the prescribing information supplied with the medication. Semaglutide is a prescription medicine and may not be appropriate for everyone. Always follow the exact product label and instructions from a licensed healthcare professional. Seek urgent medical care for a suspected medical emergency.

Additional information

PACK SIZE

20 Tablet's, 40 Tablet's, 60 Tablet's

Reviews

There are no reviews yet.

Be the first to review “Semaglutide 14 mg (Rybelsus)”

Your email address will not be published. Required fields are marked *

FAQs

What is semaglutide 14 mg?
Semaglutide 14 mg is an oral dosage strength. In the FDA-approved Rybelsus 3/7/14 mg regimen it is the higher maintenance strength.  
When is Rybelsus 14 mg used?
The FDA-approved regimen allows an increase to 14 mg on Day 61 or later if additional glycemic control is needed after 7 mg, subject to clinician direction.
Is 14 mg better than 7 mg?
Not necessarily. The appropriate strength depends on treatment response, tolerability and the prescriber’s assessment.  
How is Rybelsus 14 mg taken?
The FDA label instructs once-daily use on an empty stomach in the morning with up to 4 ounces of water, followed by at least 30 minutes before food, other beverages or other oral medicines.
When is Rybelsus 14 mg used?
The FDA-approved regimen allows an increase to 14 mg on Day 61 or later if additional glycemic control is needed after 7 mg, subject to clinician direction.  
Can 14 mg oral semaglutide be substituted for an injection dose?
No direct mg-for-mg substitution should be assumed. Oral and injectable semaglutide formulations have different dosing instructions.
Is “generic Rybelsus 14 mg” always accurate?
No. “Rybelsus” refers to a specific branded FDA-approved product, and “generic” has regulatory implications. Verify the supplied product before using either term.

Related products